January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
April 2025 in “Revista de Ciências da Saúde Nova Esperança” Botulinum Toxin Type A effectively treats various conditions with high patient satisfaction and minimal side effects.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
71 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
January 2020 in “International Research Journal of Ayurveda & Yoga” Ayurvedic treatment effectively managed Alopecia Areata, with symptoms subsiding and remaining absent for 1 year.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
March 2009 in “Hair transplant forum international” The document's conclusion cannot be provided because the content is not accessible.
December 2017 in “Journal of the American Academy of Dermatology” The patient accepted her hair loss and adapted by wearing a wig and tattooing her eyebrows.
4 citations
,
April 2025 in “Antioxidants” Alpha-ketoglutarate protects rabbit skin cells from oxidative damage by activating a specific cell pathway.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
January 2016 in “Springer eBooks” Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
March 2005 in “Journal of the American Academy of Dermatology” Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.
1 citations
,
October 2013 in “Expert Review of Dermatology” Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
19 citations
,
May 2019 in “JAMA dermatology” People with alopecia areata have similar overall death rates as others but higher risks of death from self-harm, psychiatric issues, and lung cancer in certain cases.
December 2022 in “Journal of dermatology and skin science” Androgenetic alopecia trials in the U.S. lack racial and ethnic diversity, limiting their applicability.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
13 citations
,
June 2010 in “Journal of dermatological treatment” Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.